No Detail Found!

Comparison of Anti-platelets Versus Anti-coagulants in Patients with Cryptogenic Stroke in Prevention of Recurrent Stroke and TIA

Author(s)
Muhammad Ali Yousaf Combined Military Hospital Quetta, Pakistan
Zill-e-Humayun Mirza Pakistan Naval Ship Shifa Hospital Karachi, Pakistan
Fawad Ahmad Pakistan Naval Ship Hafeez Islamabad Pakistan
Muhammad Javad Yousaf Army Medical College/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Hussain Combined Military Hospital Quetta, Pakistan
Abstract
Objective: To compare the efficacy of anti-platelets and anti-coagulants in patients with cryptogenic stroke in prevention of recurrent stroke and TIA. Study Design: Cross-sectional comparative study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Quetta, from Jan 2017 to Dec 2017. Material and Materials: Total of 30 patients with cryptogenic stroke fulfilling the inclusion/exclusion criteria were included in study, 22 were males and 08 females. They were divided into two groups with 15 patients in each. Group A was treated with anti-platelets and group B with anti-coagulants.1.5 tesla MRI was used to assess the results of the two therapies. Results: About 46.67% (n=7) in group A and 6.67% (n=1) in group B had repeated ischemic stroke (p-vlaue=0.01). 40% (n=6) in group A and 13.33% (n=2) in group B had TIA like episodes at one year (p-vlaue=0.02). Conclusion: Anti-coagulants were more effective in secondary stroke prevention in cryptogenic stroke as compared to anti-platelets at one year, provided no contraindications were present to either.
Publication Details
Page(s) 784-787
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 68, Issue: 4, Year: 2018

Request the full text from PASTIC

References
LiL,YiinGS,GeraghtyOC,SchulzUG,KukerW,MehtaZ, 2015.Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study,Lancet Neurol 14 903 -13
HartRG,SharmaM,MundlH,ShoamaneshA,KasnerSE,BerkowitzSD, 2016.Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial,EurStroke J 1 146 -54
PereraKS,VanasscheT,BoschJ,GiruparajahM,SwaminathanB,MattinaKR, 2016.Embolic strokes of undetermined source: Prevalence and patient features inthe ESUS Global Registry,Int J Stroke 11 526 -33
HartRG,DienerHC,CouttsSB,EastonJD,GrangerCB,O'Donnell MJ, 2014.Embolic strokes of undetermined source: The case for a new clinical construct,Lancet Neurol 13 429 -38
HartRG,CataneseL,PereraKS,NtaiosG,ConnollySJ, 2017.Embolic stroke of undetermined source: A systematic review and clinical update,Stroke 48 867 -72
ScheitzJF,NolteCH,LaufsU,EndresM. Application, 2015.and interpretation of high sensitivity cardiac troponin assays in patients with acute ischemic stroke,Stroke 46 1132 -40
ConnollySJ,EikelboomJ,JoynerC,DienerHC,HeartR,GolitsynS, 2011.Apixaban in patients with atrial fibrillation,N Engl J Med 364 806 -17
RuffCT,GiuglianoRP,BrauwaldE,HoffmanEB,DeenadayaluN,EzekowitzMD, 2014.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials,Lancet 383 955 -62
HoriM,MatsumotoM,TanashashiN,MomomuraS,UchiyamaS,GotoS, 2012.Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation,The J-ROCKET AF Study. Circ J 76 2104 -11
Sharma M. Embolic, 2017.Stroke of Uncertain Source: An entity slowly coming into focus,J Am Heart Assoc 6 e007286 -
BangOY,OvbiageleB,KimJS, 2014.Evaluation of cryptogenic stroke with advanceddiagnostic techniques,Stroke 45 1186 -94
GiruparajahM,BoschJ,VanasscheT,MattinaK,ConnollySJ,PaterC, 2015.Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke,Int J Stroke 10 1031 -6
ChoeWC,PassmanRS,BrachmannJ,MorilloCA,SannaT,BernsteinRA, 2015.A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the Cryptogenic Stroke and Underlying AF Trial),Am J Cardiol 116 889 -93
GladstoneDJ,SpringM,DorianP,PanzovV,ThorpeKE,HallJ, 2014.Atrialfibrillation in patients with cryptogenic stroke,N Engl J Med 370 2467 -77
HealeyJS,ConnollySJ,GoldMR,IsraelCW,Van GelderIC,CapucciA, 2012.Subclinical atrial fibrillation and the risk of stroke,N Engl J Med 366 120 -9
SaccoRL,PrabhakaranS,ThompsonJL,MurphyA,SciaccaRR,LevinB, 2006.Comparison of warfarin versus aspirin for the prevention of recurrent stroke ordeath: Subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study,Cerebrovasc Dis 22 4 -12
MerklerAE,GialdiniG,MurthySB,Salehi OmranS,MoyaA,LerarioMP, 2017.Association between troponin levels and embolic stroke of undetermined source,J Am Heart Assoc 6 e005905 -
0

Citations

0

Downloads

152

Views